This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
VP Field and Clinical Operations
Mr Ginou manages the Field and Clinical Operations at BrainsWay.
Prior to this, he served as the Clinical Trials Manager at BrainsWay, conducting dozens of clinical trials at different phases to explore the efficacy and safety of BrainsWay Deep TMS for diverse clinical indications.
Amit holds a B.Sc. degree in Neuroscience from Bar-Ilan University, and an MA Law degree from Bar-Ilan University.